PT  - JOURNAL ARTICLE
AU  - Akinci, Tuba
AU  - Derle, Eda
AU  - Kibaroğlu, Seda
AU  - Harman, Ali
AU  - Kural, Feride
AU  - Cınar, Pınar
AU  - Kilinc, Munire
AU  - Akay, Hakki T.
AU  - Can, Ufuk
AU  - Benli, Ulku S.
TI  - Clinical results of carotid artery stenting versus carotid endarterectomy
AID  - 10.17712/nsj.2016.4.20160079
DP  - 2016 Oct 01
TA  - Neurosciences Journal
PG  - 319--325
VI  - 21
IP  - 4
4099  - http://nsj.org.sa/content/21/4/319.short
4100  - http://nsj.org.sa/content/21/4/319.full
SO  - Neurosciences (Riyadh)2016 Oct 01; 21
AB  - Objective: To review our results of carotid artery stenting (CAS) and carotid endarterectomy (CEA).Methods: We evaluated the medical records of patients undergoing carotid artery revascularization procedure, between 2001 and 2013 in Baskent University Hospital, Ankara, Turkey. Carotid artery stenting or CEA procedures were performed in patients with asymptomatic carotid stenosis (≥70%) or symptomatic stenosis (≥50%). Demographic data, procedural details, and clinical outcomes were recorded. Primary outcome measures were in 30-day stroke/transient ischemic attacks (TIA)/amaurosis fugax or death. Secondary outcome measures were nerve injury, bleeding complications, length of stay in hospital, stroke, restenosis (ICA patency), and all-cause death during long-term follow-up.Results: One hundred ninety-four CEA and 115 CAS procedures were performed for symptomatic and/or asymptomatic carotid artery stenosis. There is no significant differences 30-day mortality and neurologic morbidity between CAS (13%) and CEA procedures (7.7%). Length of stay in hospital were significantly longer in CEA group (p=0.001). In the post-procedural follow up, only in symptomatic patients, restenosis rate was higher in the CEA group (p=.045). The other endpoints did not differ significantly.Conclusions: Endovascular stent treatment of carotid artery atherosclerotic disease is an alternative for vascular surgery, especially for patients that are high risk for standard CEA. The increasing experience, development of cerebral protection systems and new treatment protocols increases CAS feasibility.